Here are the 424B prospectus supplements from IN8bio, Inc. (INAB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow INAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INAB filings page.
IN8bio, Inc. is registering an at-the-market offering to sell up to $2,800,000 aggregate offering price of its common stock through JonesTrading Institutional Services LLC under a Sales Agreement. Sales may occur from time to time at prevailing market prices; JonesTrading will act as agent (or principal) and receive 3.0% of gross proceeds as compensation.
The prospectus supplement ties the offering to our existing Form S-3 shelf and states shares outstanding were 9,847,089 as of March 31, 2026. The filing discloses the aggregate market value of common stock held by non-affiliates as $17,932,668 as of June 1, 2026 (based on 9,589,662 non-affiliate shares at $1.87). Proceeds, if any, are intended for clinical development, working capital and general corporate purposes.
IN8bio, Inc. has filed a resale prospectus covering up to 14,384,052 shares of common stock for sale by existing investors, and the company will not receive any proceeds from these sales. The shares relate to a December 22, 2025 private placement of 4,931,375 PIPE Shares and 9,452,677 shares issuable on exercise of pre-funded warrants.
The pre-funded warrants are immediately exercisable at $0.0001 per share, subject to beneficial ownership limits of up to 19.99%. IN8bio previously received approximately $18.6 million in net proceeds from the initial private placement closing. The stock trades on Nasdaq Capital Market under the symbol INAB.